Article info
PDFCardiac risk factors and prevention
Original research
Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
- Correspondence to Professor Lamberto Manzoli, Medical Sciences, University of Ferrara, Ferrara 44121, Italy; lmanzoli{at}post.harvard.edu
Citation
Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
Publication history
- Received May 13, 2020
- Revised June 9, 2020
- Accepted June 17, 2020
- First published July 1, 2020.
Online issue publication
March 31, 2021
Article Versions
- Previous version (31 March 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.